abstract |
Declared liquid compositions for subcutaneous administration, containing immunoglobulin (Ig) at a concentration of at least 10% w / v, soluble hyaluronidase at a concentration of at least 50 units / ml, which is present in a ratio of at least 100 units / g Ig , alkali metal chloride at a concentration of at least 50 mM, having a pH of about 4 to 5 and stable at 28-32 ° C for at least 6 months; containers containing a stable liquid joint composition, and kits containing a stable liquid joint composition, or containers; A method of treating amenable immunoglobulin diseases or conditions, including subcutaneous administration to the subject of a stable liquid co-formulation, as well as the use of a stable liquid co-formulation to prepare a drug for treating an Ig-treatable disease or condition. |